1. An antiallergic composition comprising as active ingredients the lactic acid bacteria showing equal interleukin 12 production level compared to when Lactobacillus paracasei KW 3110 strain is used as the lactic acid bacteria to be tested, or showing 60% or more of interleukin 12 production level compared to when Lactobacillus paracasei KW 3110 strain is used, and showing less than 50% of interleukin 4 production level of a control wherein the lactic acid bacteria are not added, in case lymphocytes derived from mouse spleen sensitized with ovalbumin are suspended in a medium containing ovalbumin, and cultured by adding the lactic acid bacteria to be tested.
2. The antiallergic composition according to claim 1, comprising as active ingredients the lactic acid bacteria showing equal interleukin 12 production level compared to when Lactobacillus paracasei KW 3110 strain is used as the lactic acid bacteria to be tested, or showing 75% or more of interleukin 12 production level compared to when Lactobacillus paracasei KW 3110 strain is used, in case lymphocytes derived from mouse spleen sensitized with ovalbumin are suspended in a medium containing ovalbumin, and cultured by adding the lactic acid bacteria to be tested.
3. The antiallergic composition according to claim 1, wherein the lactic acid bacteria showing less than 40% of interleukin 4 production level compared to control wherein the lactic acid bacteria are not added are comprised as active ingredients, in case lymphocytes derived from mouse spleen sensitized with ovalbumin are suspended in a medium containing ovalbumin, and cultured by adding the lactic acid bacteria to be tested.
4. The antiallergic composition according to claim 1, wherein the lactic acid bacteria showing equal interleukin 12 production level compared to when Lactobacillus paracasei KW 3110 strain is used as the lactic acid bacteria to be tested, or showing 75% or more of interleukin 12 production level compared to when Lactobacillus paracasei is used, and showing less than 40% of interleukin 4 production level of a control, wherein the lactic acid bacteria are not added, are added as active ingredients, in case lymphocytes derived from mouse spleen sensitized with ovalbumin are suspended in a medium containing ovalbumin, and cultured by adding the lactic acid bacteria to be tested.
5. The antiallergic composition according to claim 1, wherein the lactic acid bacteria showing equal interleukin 12 production level compared to when Lactobacillus paracasei KW 3110 strain is used as the lactic acid bacteria to be tested, or showing 80% or more of interleukin 12 production level compared to when Lactobacillus paracasei KW 3110 strain is used, and showing less than 30% of interleukin 4 production level of a control wherein the lactic acid bacteria are not added as active ingredients, in case lymphocytes derived from mouse spleen sensitized with ovalbumin are suspended in a medium containing ovalbumin, and cultured by adding the lactic acid bacteria to be tested.
6. An antiallergic composition, wherein the lactic acid bacteria showing the interleukin 12 and interleukin 4 production levels of the lymphocytes derived from mouse spleen according to claim 1 is Lactobacillus. paracasei KW3110 strain, Lactobacillus plantarum KW4110 strain, Lactobacillus paracasei KW3925 strain, Lactobacillus. paracasei KW3926 strain or Streptococcus salivarius KW3210 strain.
7. An antiallergic composition having as active ingredients Lactobacillus paracasei KW3110 strain, which shows interleukin 12 production level and interleukin 4 production levels of the lymphocytes derived from mouse spleen according to claim 1, and which resistant to digestive juice, and highly adhesive to intestinal tract.
8. The antiallergic composition according to claim 1, wherein allergy is pollinosis, bronchial asthma, allergic rhinitis, allergic conjunctivitis or atopic dermatitis.
9. The antiallergic composition according to claim 8, wherein the antiallergic composition is a medicine.
10. The antiallergic composition according to claim 8, wherein the antiallergic composition is foods or drinks.
11. A method for obtaining the lactic acid bacteria with high antiallergic activity, wherein lymphocytes derived from mouse spleen sensitized with ovalbumin are suspended to a medium containing ovalbumin and cultured by adding the lactic acid bacteria to be tested, and by separating the lactic acid bacteria showing equal interleukin 12 production level compared to when Lactobacillus paracasei KW3110 strain are used as the lactic acid bacteria to be tested or 60% or more of interleukin 12 production level compared to when Lactobacillus paracasei KW3110 strain are used, and showing less than 50% of interleukin 4 production level of a control wherein the lactic acid bacteria are not added.
12. A method for producing the lactic acid bacteria with high antiallergic activity, wherein the lactic acid bacteria separated by the method according to claim 11 is cultured in a medium, and proliferated.
13. The method for producing the lactic acid bacteria with high antiallergic activity according to claim 12, wherein the high antiallergic activity of the lactic acid bacteria cultured in a medium and proliferated is verified.
14. The method for producing the lactic acid bacteria with high antiallergic activity according to claim 13, wherein the verification of the high antiallergic activity of the lactic acid bacteria proliferated is carried out by culturing lymphocytes derived from mouse spleen sensitized with ovalbumin suspended to a medium containing ovalbumin, by adding the lactic acid bacteria, and by measuring the interleukin 12 and interleukin 4 production levels.
15. A method for producing drug medicine or foods or drinks in a sealed container, wherein the lactic acid bacteria produced by the method for producing the lactic acid bacteria with high antiallergic activity according to claim 12 is compound in drug medicine or foods or drinks, filled and sealed into a container.
16. A method for preventing andor treating allergic diseases wherein the antiallergic compositions according to any one of claims 1 to 10 are used in a treatment of prevention andor treatment of allergic diseases.
17. The method for preventing andor treating allergic diseases according to claim 16, wherein the allergic diseases are pollinosis, bronchial asthma, allergic rhinitis, allergic conjunctivitis or atopic dermatitis.
18. Use of antiallergic composition according to claim 1 for the prevention andor treatment of allergic diseases.
19. The use of the antiallergic composition according to claim 18, wherein the prevention andor treatment of allergic diseases is the prevention andor treatment of pollinosis, bronchial asthma, allergic rhinitis, allergic conjunctivitis or atopic dermatitis.
20. Foods or drinks with antiallergic activity wherein the lactic acid bacteria with antiallergic activity according to claim 1 is added as active ingredients.
21. The foods or drinks having antiallergic activity according to claim 20, wherein the lactic acid bacteria with high antiallergic activity are contained by 5\xd7109 or more in a daily intake amount of foods or drinks.
22. The foods or drinks with antiallergic activity according to claim 20, wherein the beverage or food does not contain ingredients to be the cause of allergy.
23. The foods or drinks with antiallergic activity according to claim 22, wherein the beverage or food is a tablet, granule, powder, capsule or health drink that does not contain ingredients to be the cause of allergy.
24. The foods or drinks with antiallergic activity according to claim 20, wherein the lactic acid bacteria are used after sterilization.
25. A beverage with antiallergic function wherein the lactic acid bacteria with antiallergic activity according to claim is added as active ingredients.
26. The beverage with antiallergic function according to claim 22, wherein the beverage is a nondairy beverage in a sealed container.
27. The beverage with antiallercic function according to claim 25, wherein the beverage is a soft drink containing juice or a tea drink in a sealed container.
28. The beverage with antiallergic function according to claim 25, wherein the number of lactic acid bacteria to be added in a beverage is between 109 and 1011 per 100 g of beverage in the sealed container.
29. A food or drink with antiallergic function according to claim 20, wherein the lactic acid bacteria to be added are Lactobacillus paracasei KW3110 or its variant.
30. The food or beverage with antiallergic activity according to claim 20, wherein the food or beverage is prepared as health foods, functional foods, specified health foods, or patient foods.
31. A method for producing food or drink in a sealed container with antiallergic function, wherein the lactic acid bacteria with high antiallergic activity according to claim 1, or the lactic acid being sterilized are compound substantively under a sterilized condition, filled and sealed in a container.
32. A method for measuring antiallergic activity of the lactic acid bacteria wherein the level of interleukin 12 or interleukin 4 generated by suspending lymphocytes derived from mouse spleen sensitized with ovalbumin to a medium containing ovalbumin and cultured by adding the lactic acid bacteria to be tested.
33. The method for measuring antiallergic activity of the lactic acid bacteria according to claim 32, wherein the level of interleukin 12 or interleukin 4 generated by adding the lactic acid bacteria to be tested and cultured is estimated by comparing with when Lactobacillus paracasei KW3110 strain is used.
34. An antiallergic agent formulated by adding carrier, excipient andor other adjuvant to the lactic acid bacteria with high antiallergic activity according to claim 1.
35. A drug medicine comprising the lactic acid bacteria with high antiallergic activity according to claim 1.
36. A food or drink with antiallergic activity, wherein a part or whole of the food or drink produced by using the lactic acid bacteria or the food or drink containing the lactic acid bacteria are replaced by the lactic acid bacteria with high antiallergic activity according to claim 1.
37. A method for producing beverage or food with antiallergic function, wherein a part of whole of the beverage or food produced by using the lactic acid bacteria or the beverage or food comprising the lactic acid bacteria are replaced by the lactic acid bacteria with high antiallergic activity according to claim 1.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-26. (Cancelled)
27. A method for providing a terminal with a service from a service centre, the terminal and the service centre being connected by a communication network, the method comprising:
transmitting from the terminal to the service centre a request for the service;
adding the terminal to a queue for the service;
transmitting from the terminal a request for one or more indications of the status of the terminal in the queue;
transmitting to the terminal by a first form of connection the one or more indications;
determining that the service centre is ready to provide the terminal with the service;
establishing a session between the terminal and the service centre using a second form of connection having greater network demands than the first form of connection; and
providing the terminal with the service using the session.
28. A method as claimed in claim 27, including the steps of:
receiving the request; and
determining whether the service centre is ready to provide the terminal with the service;
and wherein the steps of adding the terminal to a queue for the service and transmitting to the terminal by a first form of connection one or more indications of the status of the terminal in the queue are performed only if it is determined that the service centre is not ready to provide the terminal with the service.
29. A method as claimed in claim 27, wherein the request for the service is transmitted in a packet format.
30. A method as claimed in claim 27, wherein the request for the service is transmitted in SIP format.
31. A method as claimed in claim 27, comprising the steps of:
transmitting to the terminal an indication of the address of an indication server from which the one or more indications of the status of the terminal in the queue may be received; and
transmitting from the terminal to the said address a request for the one or more indications.
32. A method as claimed in claim 31, wherein the indication of the address of the indication server is transmitted in SIP format.
33. A method as claimed in claim 31, wherein the request for the one or more indications is transmitted in HTTP format.
34. A method as claimed in claim 27, wherein the said one or more indications are transmitted in a packet format.
35. A method as claimed in claim 27, wherein the said one or more indications are transmitted in HTML format.
36. A method as claimed in claim 27, wherein the said one or more indications include data in HTML format.
37. A method as claimed in claim 27, wherein the said one or more indications include an applet for execution at the terminal and the method includes the step of executing the applet.
38. A method as claimed in claim 27, comprising transmitting a plurality of the indications of the status of the terminal and wherein the said indications are pushed from an indication server to the terminal.
39. A method as claimed in claim 27, comprising transmitting a plurality of the indications of the status of the terminal and wherein each said indication is transmitted from the indication server to the terminal in response to a respective request transmitted from the terminal to the indication server.
40. A method as claimed in claim 27, comprising the step of, on determining that the service centre is ready to provide the terminal with the service, transmitting to the terminal an invitation to establish the session.
41. A method as claimed in claim 40, wherein the invitation to establish the session is transmitted in SIP format.
42. A method as claimed in claim 27, wherein the network demands include at least one of: bandwidth, reduced latency, reduced jitter and reduced delay.
43. A method as claimed in claim 27, wherein the second form of connection is a real-time connection.
44. A service provision system for providing a terminal with a service from a service centre, the terminal and the service centre being connected by a communication network, the service centre comprising:
a messaging arrangement capable of communicating with the terminal by means of a messaging protocol;
an indication server capable of receiving from the terminal a request for one or more indications of the status of the terminal in the queue and transmitting to the terminal by a first form of connection the one or more indications;
a data store for storing information defining the status of one or more terms in a queue for the service; and
an agent capable of providing the service to the terminal using a session between the terminal and the service centre using a second form of connection having greater network demands than the first form of connection;
and wherein the messaging arrangement is arranged to, in response to a request for the service from the terminal by means of the messaging protocol, determine whether the service centre is ready to provide the service and if it is not ready to provide the service to send a message indicating that it should request from the indication server an indication of the status of the terminal in the queue.
45. A method according to claim 27, wherein said terminal comprises a web browser for receiving information from said service centre in a visual form and for alerting the user of said terminal when the session is to begin.
46. A method according to claim 45, wherein the alert is in the form of an audible alarm.
47. A method according to claim 45, wherein the alert is an eye-catching animation on the display of said terminal.
48. A system for providing a terminal with a service from a service centre, the terminal and service centre being connected by a communications network and the service centre comprising:
a plurality of service agents, each for providing a directory enquiry service;
a routing unit for routing incoming requests for directory enquiry services from the terminal to the service agents; and
a queuing control unit for managing the queuing of said requests having a SIP application and a web application for storing the queue on a data store.
49. A method of communication using the system of claim 48, wherein a session is established between the terminal and least one of said service agents by performing the steps of:
i) the terminal sending a request for a new session to the service centre where it is routed by said routing unit to said corresponding SIP application;
ii) the SIP application querying the web application to check the status of the queue held in the data store;
iii) if a queue exists, the web application adding the terminal to the queue and the SIP application sending to the terminal response indicating the address of the web application; and
iv) the terminal acting on said response by accessing the corresponding web application using said address and retrieving an indication of the current status of the terminal in the queue;
v) when the web application determines a service agent is free, sending the address of said free agent to the SIP application; and
vi) said SIP application connecting the terminal to said free agent and the session being started.
50. A method according to claim 49, wherein said request in step i) is in the form of a SIP INVITE message.
51. A method according to claim 49, wherein the response in step ii) is the form of a SIP response and the address is the uniform resource locator (URL) of the web application.
52. A method according to claim 49, wherein if there is no queue after step ii) is performed the web application sends a message to cause the session to begin.